Back

Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell epitope mapping

Schreibing, F.; Hannani, M.; Ticconi, F.; Fewings, E.; Nagai, J. S.; Begemann, M.; Kuppe, C.; Kurth, I.; Kranz, J.; Frank, D.; Anslinger, T. M.; Ziegler, P.; Kraus, T.; Enczmann, J.; Balz, V.; Windhofer, F.; Balfanz, P.; Kurts, C.; Marx, G.; Marx, N.; Dreher, M.; Schneider, R. K.; Saez-Rodriguez, J.; Costa Filho, I. G.; Kramann, R.

2021-03-03 immunology
10.1101/2021.03.03.432690 bioRxiv
Show abstract

The current COVID-19 pandemic represents a global challenge. A better understanding of the immune response against SARS-CoV-2 is key to unveil the differences in disease severity and to develop future vaccines targeting novel SARS-CoV-2 variants. Feature barcode technology combined with CITE-seq antibodies and DNA-barcoded peptide-MHC I Dextramer reagents enabled us to identify relevant SARS-CoV-2-derived epitopes and compare epitope-specific CD8+ T cell populations between mild and severe COVID-19. We identified a strong CD8+ T cell response against an S protein-derived epitope. CD8+ effector cells in severe COVID-19 displayed hyperactivation, T cell exhaustion and were missing characteristics of long-lived memory T cells. We identify A*0101 WTAGAAAYY as an immunogenic CD8+ T cell epitope with the ability to drive clonal expansion. We provide an in-depth characterization of the CD8+ T cell-mediated response to SARS-CoV-2 infection which will be relevant for the development of molecular and targeted therapies and potential adjustments of vaccination strategies.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.